Emzor Pharmaceutical Industries Ltd (Emzor), a leading light in the Nigerian pharmaceutical sector, has announced the successful repayment of its inaugural Series 1 Commercial Paper. Originally issued in November 2024, under its ₦10 billion Commercial Paper Issuance Programme, the ₦5.13 billion note matured on August 18, 2025, marking a significant milestone in the company’s capital markets journey.
This fulfilment and the continued retention of its investment-grade credit rating of A- with a stable outlook (GCR) further reinforce Emzor’s credibility and financial discipline in Nigeria’s investment landscape.
Beyond this financial triumph, the company says, it continues to drive innovation, quality, self-reliance, and excellence in pharmaceutical manufacturing.
The company has successfully scaled up local API (active pharmaceutical ingredients) production with a $23 million transformative investment. Situated in Sagamu, Ogun State,
The $23 million API plant is the first of its kind in Sub-Saharan Africa. This venture is set to bolster Nigeria’s drug self-sufficiency by reducing import reliance and lowering production costs, especially for vital medicines like antimalarials and HIV/AIDS antiretrovirals.The API Plant nearing completion was initially slated for opening in Q1-2024, but the timeline has been revised to early 2026, owing to fiscal, monetary, and regulatory complexities. Despite these pressures, the project is advancing swiftly, with over 90% of civil engineering works completed and critical production equipment already installed. The API R&D laboratory has already developed and synthesized five antimalarial APIs in anticipation of full-scale production.
Emzor Pharmaceutical continues to sustainably champion drug safety with innovative track-and-trace technology. Demonstrating a steadfast commitment to quality and consumer safety, Emzor has rolled out an advanced ERP, Oracle, as well as a track-and-trace software system across its supply chain. These solutions support lean manufacturing, tighten inventory management, and strengthen market surveillance, helping to eliminate substandard and counterfeit medications, especially in underserved areas.
